Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)

Inclusion Criteria: Clinical: * Diabetic patients with active treatment (oral agent or insulin) * Patients with angina and documented ischemia or patients with documented silent ischemia * Patients who are eligible for intracoronary stenting * Age \> 20 years, \< 75 years Angiographic: * De novo lesion * Percent diameter stenosis ≥ 50% * Reference vessel size ≥ 2.5 mm by visual estimation Exclusion Criteria: 1. History of bleeding diathesis or coagulopathy 2. Pregnant state 3. Known hypersensitivity or contra-indication to contrast agent and heparin 4. Limited life-expectancy (less than 1 year) 5. ST-elevation acute myocardial infraction requiring primary stenting 6. Characteristics of lesion: left main disease, in-stent restenosis, graft vessels 7. Hematological disease (Neutropenia \< 3000/mm3), Thrombocytopenia \< 100,000/mm3) 8. Hepatic dysfunction, liver enzyme (ALT and AST) elevation ≥ 3times normal 9. Renal dysfunction, creatinine ≥ 2.0mg/dL 10. Contraindication to aspirin, clopidogrel or cilostazol 11. Contraindication to Paclitaxel or everolimus 12. Left ventricular ejection fraction \< 30% 13. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period 14. Non-cardiac co-morbid conditions are present with life expectancy \< 1 year or that may result in protocol non-compliance (per site investigator's medical judgment for example: oxygen dependent chronic obstructive pulmonary disease, active hepatitis or severe liver function or kidney disease)